Zoetis Inc (ZTS)
Pretax margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) | US$ in thousands | 2,940,000 | 2,659,000 | 2,491,000 | 1,998,000 | 1,801,000 |
Revenue | US$ in thousands | 8,544,000 | 8,080,000 | 7,776,000 | 6,675,000 | 6,260,000 |
Pretax margin | 34.41% | 32.91% | 32.03% | 29.93% | 28.77% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $2,940,000K ÷ $8,544,000K
= 34.41%
The pretax margin of Zoetis Inc has shown a consistent upward trend over the past five years, indicating improving profitability before taxes. From 2019 to 2023, the pretax margin has increased from 28.77% to 34.36%, reflecting the company's ability to generate earnings relative to its total revenue. This upward trajectory suggests effective cost management and operational efficiency, leading to higher profitability for Zoetis Inc. The steady growth in pretax margin signifies the company's strong financial performance and potentially sustainable competitive advantage in the market.
Peer comparison
Dec 31, 2023
Company name
Symbol
Pretax margin
Zoetis Inc
ZTS
34.41%
Abbott Laboratories
ABT
16.90%
AbbVie Inc
ABBV
11.49%
Alkermes Plc
ALKS
15.74%
Amphastar P
AMPH
26.28%
ANI Pharmaceuticals Inc
ANIP
4.37%
Arcus Biosciences Inc
RCUS
-257.26%
Biomarin Pharmaceutical Inc
BMRN
7.94%
Bristol-Myers Squibb Company
BMY
18.72%
Catalent Inc
CTLT
-23.44%
Catalyst Pharmaceuticals Inc
CPRX
23.73%